Pancreatic cancer: New treatment approved

The pharmaceutical group Helvetic got the green light from European authorities to market a new specialty drug for the treatment of cancer tumors called "neuroendocrine" of the pancreas. A phase III clinical study, on which the approval of the European Commission, showed that everolimus reduced by 65% ​​the risk of cancer progression compared to placebo treatment, said the lab in a statement.